Trading Halt, page-48

Thanks 6186.

I found this from the NYT, also 2008 so prices may have changed. Bold is mine.

'The drug’s price, as charged by Genentech, can be $4,000 to more than $9,000 a month, depending on a patient’s weight and the type of cancer. Avastin’s cost to patients and insurers can be much higher, though, because doctors and hospitals buy the drug and then sell it to patients or their insurers, often marking up the price. So the $2.3 billion that Genentech recorded in sales of Avastin represents only part of what Americans spent on the drug last year. '

Apparently it is sold as an ongoing treatment until progression stops. So it could be a few months or potentially a lot longer.

In any case it is a nasty drug, and am most interested in the SIRFLOX data. SRX will have to cross validate any data that shows SIRT as good as Bev, as the consequences of publishing challengeable data could be very costly from a legal point of view.